1. Home
  2. ZYME vs CFFN Comparison

ZYME vs CFFN Comparison

Compare ZYME & CFFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • CFFN
  • Stock Information
  • Founded
  • ZYME 2003
  • CFFN 1893
  • Country
  • ZYME United States
  • CFFN United States
  • Employees
  • ZYME N/A
  • CFFN N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • CFFN Savings Institutions
  • Sector
  • ZYME Health Care
  • CFFN Finance
  • Exchange
  • ZYME Nasdaq
  • CFFN Nasdaq
  • Market Cap
  • ZYME 846.1M
  • CFFN 759.7M
  • IPO Year
  • ZYME 2017
  • CFFN 1999
  • Fundamental
  • Price
  • ZYME $11.43
  • CFFN $5.71
  • Analyst Decision
  • ZYME Buy
  • CFFN Hold
  • Analyst Count
  • ZYME 7
  • CFFN 2
  • Target Price
  • ZYME $19.50
  • CFFN $6.50
  • AVG Volume (30 Days)
  • ZYME 449.0K
  • CFFN 1.1M
  • Earning Date
  • ZYME 05-08-2025
  • CFFN 07-23-2025
  • Dividend Yield
  • ZYME N/A
  • CFFN 5.95%
  • EPS Growth
  • ZYME N/A
  • CFFN N/A
  • EPS
  • ZYME N/A
  • CFFN 0.40
  • Revenue
  • ZYME $93,384,000.00
  • CFFN $184,847,000.00
  • Revenue This Year
  • ZYME $34.23
  • CFFN $9.81
  • Revenue Next Year
  • ZYME $68.78
  • CFFN $9.80
  • P/E Ratio
  • ZYME N/A
  • CFFN $14.14
  • Revenue Growth
  • ZYME 85.05
  • CFFN N/A
  • 52 Week Low
  • ZYME $8.21
  • CFFN $4.90
  • 52 Week High
  • ZYME $17.70
  • CFFN $7.20
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 45.92
  • CFFN 51.61
  • Support Level
  • ZYME $11.46
  • CFFN $5.64
  • Resistance Level
  • ZYME $11.81
  • CFFN $5.92
  • Average True Range (ATR)
  • ZYME 0.59
  • CFFN 0.14
  • MACD
  • ZYME -0.05
  • CFFN -0.01
  • Stochastic Oscillator
  • ZYME 27.62
  • CFFN 48.78

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About CFFN Capitol Federal Financial Inc.

Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank, Capitol Federal Savings Bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It primarily serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.

Share on Social Networks: